A phase 2, open-label, multicenter study of INCAGN01876 (anti-GITR agonist) in combination with retifanlimab (anti–PD-1) in recurrent or metastatic head and neck squamous cell carcinoma

Rom Leidner; Robert Haddad; Nawel Bourayou; Sonia Ioannidis; Feng Zhou; Zhiwan Dong; Ezra Cohen

A phase 2, open-label, multicenter study of INCAGN01876 (anti-GITR agonist) in combination with retifanlimab (anti–PD-1) in recurrent or metastatic head and neck squamous cell carcinoma

Rom Leidner, Robert Haddad, Nawel Bourayou, Sonia Ioannidis, Feng Zhou, Zhiwan Dong, Ezra Cohen

Research output: Other contribution

Original language	Undefined/Unknown
State	Published - Nov 8 2022

Publication series

Name	Articles, Abstracts, and Reports

Access to Document

http://digitalcommons.psjhealth.org/publications/6982

Cite this

@misc{7ac64375c93d4ea281f37c0c2576e6e5,

title = "A phase 2, open-label, multicenter study of INCAGN01876 (anti-GITR agonist) in combination with retifanlimab (anti–PD-1) in recurrent or metastatic head and neck squamous cell carcinoma",

author = "Rom Leidner and Robert Haddad and Nawel Bourayou and Sonia Ioannidis and Feng Zhou and Zhiwan Dong and Ezra Cohen",

year = "2022",

month = nov,

day = "8",

language = "Undefined/Unknown",

series = "Articles, Abstracts, and Reports",

type = "Other",

}

TY - GEN

T1 - A phase 2, open-label, multicenter study of INCAGN01876 (anti-GITR agonist) in combination with retifanlimab (anti–PD-1) in recurrent or metastatic head and neck squamous cell carcinoma

AU - Leidner, Rom

AU - Haddad, Robert

AU - Bourayou, Nawel

AU - Ioannidis, Sonia

AU - Zhou, Feng

AU - Dong, Zhiwan

AU - Cohen, Ezra

PY - 2022/11/8

Y1 - 2022/11/8

M3 - Other contribution

T3 - Articles, Abstracts, and Reports

ER -